08:21:16 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaOAX Equities
SektorHälsovård
IndustriMedicinteknik
Observe Medical är ett norskt bolag verksamma inom medicinteknik. Bolaget bedriver utveckling av tekniska instrument som används inom intensivvården. Produkterna säljs under olika varumärken och är särskilt specialiserade för urinmätning. Störst verksamhet återfinns inom den nordiska - samt europeiska marknaden. Bolaget kom till som en avknoppning från Navamedic och har sitt huvudkontor i Oslo.

Kalender

2021-11-03 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2
2021-05-25 Ordinarie utdelning OBSRV 0.00 NOK
2021-05-21 Årsstämma 2021
2021-05-12 Kvartalsrapport 2021-Q1
2021-02-23 Bokslutskommuniké 2020
2020-11-03 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning OBSRV 0.00 NOK
2020-06-30 Årsstämma 2020
2020-06-16 Extra Bolagsstämma 2020
2020-05-12 Kvartalsrapport 2020-Q1
2020-02-25 Bokslutskommuniké 2019
2021-02-22 08:50:38
Oslo February 22, 2021 - Observe Medical ASA (OSE: OBSERV), announces that Nya
Karolinska Sjukhuset in Stockholm, Sweden resumes the implementation of Sippi®
in clinical use at the Cardiothoracic ICU unit following a pause during 2020,
due to Covid-19

As a result of the recent improvements of the Covid-19 situation at the
hospital, the Department of Cardiothoracic Anaesthesiology and Intensive Care at
Nya Karolinska Sjukhuset, has decided to resume the implementation of Sippi® in
clinical use. The implementation will start in February, and will be done in a
stepwise manner, with a limited number of Sippi® units utilized in a first
phase, followed by planned full implementation at the Department later this
year. The implementation was originally initiated during early 2020 but paused
due to the constrained situation in the hospital, caused by Covid-19.

 Sippi® has previously been investigated in a clinical study at the
Cardiothoracic ICU Department at Nya Karolinska Sjukhuset. The study forms part
of the thesis "Evaluation of an automatic urinometer including use of silicone
oil to decrease biofilm formation due to proteinuria, hemoglobinuria and
bacterial growth" by Dr. Martin Slettengren who recently dissertated at the
Dept. of Molecular Medicine and Surgery, Karolinska Institute in Stockholm on
January 14, 2021 (see press release from Observe Medical on January 15, 2021).

 "We are pleased that Nya Karolinska Sjukhuset - a leading university hospital
in Europe, has decided to resume the implementation of Sippi at the
Cardiothoracic ICU Department. This may onwards serve as a reference for other
departments at the same hospital as well as at other hospitals" says Björn
Larsson, CEO Observe Medical.

Observe Medical is currently launching Sippi® automated digital urine meter with
the short-term focus of accelerating the clinical use of Sippi® in the Nordics
and selected markets in Europe.

For further information, please contact:

Observe Medical: Björn Larsson, CEO, +46 76 620 17 25,
bjorn.larsson@observemedical.com



About Observe Medical

https://observemedical.com/ Observe Medical develops, markets, and sells
innovative hospital products that contribute to increased patient safety and a
more efficient care system. The company's ambition is to drive growth by
leveraging its expertise in sales and commercialization of its broad portfolio
of medical technology products, mainly in the areas of Urine measurement,
Anesthesiology/ICUs, and wound care, in combination with targeted M&A. The
company's headquarter is in Oslo, Norway and its operations are based out of
Gothenburg, Sweden. Observe Medical has a direct sales organization in the
Nordics and a distributor network internationally. Observe Medical's product,
Sippi®, is the only automated digital urine meter with the possibility for
wireless data transfer to hospital patient data management systems and hinders
bacterial migration that can lead to urinary infections (Sippcoat®). Sippi® is
CE marked and currently being launched with a focus on selected markets and
hospitals in the Nordics and in Europe.